Slide 1: Financial Results Year Ended 31 Dec 2023
Financial Results Year Ended 31 Dec 2023
Slide 2: Vita Life Sciences Ltd
Vita Life Sciences Ltd Vita Life Sciences is an Australian owned healthcare company that is listed on the Australian Securities Exchange (ASX:VLS). Our core business is the development and Values Vita Life Sciences has a distribution of over the counter (OTC) medicines, as companywide commitment to:
Slide 3: Dividends
Dividends Fully franked dividend of 9.00 cents/ share for 2023 (6 cents final and 3 cents interim). 14th consecutive year of dividend payments to Shareholders. Annual dividend growth rate of 13.3% p.a. over the past 7 years. Record date for the final dividend of 6 cents/ share will be 25 Mar
Slide 4: Key Financial Measures
Key Financial Measures Another record: sales of Strong revenue growth $74.1m, up 10.9% on from Australia, Malaysia and with increased GROUP SALES GROUP EBIT previous corresponding A$’m A$’m period (PCP) exports into China 80 12 11 10 60 New customer 9 Group EBIT of acquisition and $12.0m, up 13% 8 i
Slide 5: Australia
Australia Revenue of $43m, an increase of 16% on PCP. New customer acquisition across the pharmacy channel continues A$’m Revenue up 16% A$’m EBIT up 27% with market share gains reported across the category based on sell 50 7 through industry data. 45 40 6 Consumer offtake domestically was par
Slide 6: Malaysia
Malaysia Revenue of $22.8m an increase of 7% on PCP. A$’m Revenue up 7% A$’m EBIT down 3% Malaysian market showcased resilience against economic and 24 competitive pressures 22 7 The business deployed a strategy to increase the VitaHealth 20 6 brand footprint across large chain pharmacies/ mod
Slide 7: Singapore
Singapore Revenue of $6.3m an increase of 7% on PCP. Increased product ranging into “modern trade” retailers supported the increased sales through traditional selling A$’m Revenue up 7% channels. 6 Increased ranging of the VitaHealth products across modern trade pharmacies, resulted in higher
Slide 8: Other Asia
Other Asia Revenue of $1.6m a decrease of 32% on PCP The Vietnam market conditions were impacted by slower economic trading conditions during the year.
Slide 9: Cashflows
Cashflows Cashflow and capital were well managed with 2023 Group operating cashflow before interest and tax of $15.9m and gross operating cashflow/ EBITDA of Gross operating cashflow to EBITDA 127%. Operating cashflow conversion improved significantly due to stronger sales and a reduction in sto
Slide 10: Priorities & Outlook
Priorities & Outlook Export sales to China are New strategic focus on Vietnam and Most domestic business across Management will continue to expected to continue leading Indonesia including new distribution the Group’s key markets are manage ongoing macro economic into major e-commerce partners to be
Slide 11: Appendix
WAVITA LIFE
Slide 12: Full Year Results
Full Year Results Income Statement for the year ended Dec 2023 2022 $’m $’m Revenue 74.1 66.9 EBITDA 12.5 11.2 EBIT 12.0 10.6 Profit before tax 12.4 10.7 Profit after tax 9.1 7.3 EPS (Basic – cents/ share) 16.92 13.37 Dividend (cents / share) 9.00 6.00
Slide 13: Balance Sheet
Balance Sheet Balance Sheet as at Dec 2023 2022 $’m $’m Current assets 48.3 41.2 Non-current assets 11.5 10.6 Total assets 59.8 51.8 Current liabilities 16.2 14.9 Non-current liabilities 0.3 0.4 Total Liabilities 16.5 15.3 Net Assets 43.3 36.5
Slide 14: Cash Flow
Cash Flow Cash Flow for the year ended Dec 2023 2022 $’m $’m Receipts from customers 76.4 69.0 Payments to suppliers and employees (60.6) (62.0) Gross operating cash flow 15.8 7.0 EBITDA 12.5 11.2 Gross operating cash flow / EBITDA 126.7% 62.5% Net interest 0.4 0.0 Income tax paid (3.3) (4.3) Operat
Slide 15: Andrew O'Keefe, Chin Lkhoo contact details
P a) / ANDREW O’KEEFE MANAGING DIRECTOR CHIN LKHOO CHIEF FINANCIAL OFFICER (e) +612 9545 2633 1/102 Bath Road, Kirrawee, NSW 2232 enquiries@vitalifesciences.com.au vitalifesciences.com VITA LIFE CIENCES
Slide 16: Disclaimer
Disclaimer This document has been prepared by Vita Life Sciences Limited (Vita Life Sciences or VLS) and comprises written material/slides for a presentation concerning Vita Life Sciences. The presentation is for information purposes only and does not constitute or form part of any offer or invitati